Yamo Pharmaceuticals
Yamo Pharmaceuticals, based in New York, NY, is focused on addressing the critical unmet needs in Autism Spectrum Disorder (ASD) treatment with its innovative therapy, L179. This therapy is designed to target core deficits in social interaction and has shown promising efficacy in recent clinical trials.
With a mechanism of action that regulates catecholamine networks and targets key pathways in both the central and autonomic nervous systems, L179 aims to enhance communication and social behavior. This approach offers new hope for individuals affected by ASD, representing a significant advancement in treatment options.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Partial Data by Foursquare.